Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Time to Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares gapped down before the market opened on Monday . The stock had previously closed at $23.34, but opened at $22.05. Ascentage Pharma Group International shares last traded at $22.2720, with a volume of 527 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Rodman & Renshaw assumed coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They set a “buy” rating and a $40.00 target price on the stock. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Finally, BTIG Research reaffirmed a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $46.67.

Ascentage Pharma Group International Stock Performance

The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The firm has a fifty day moving average price of $24.32 and a 200 day moving average price of $27.52.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The firm had revenue of $24.72 million during the quarter. Sell-side analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

Institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International in the 3rd quarter valued at about $383,000. UBS Group AG raised its holdings in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the period. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International in the 2nd quarter valued at about $391,000. XY Capital Ltd raised its holdings in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares during the period. Finally, ABC Arbitrage SA purchased a new stake in Ascentage Pharma Group International in the 3rd quarter valued at about $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.